Madrigal Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). The company's flagship product, Rezdiffra (resmetirom), is a liver-directed thyroid hormone receptor-beta (THR-beta) agonist. Rezdiffra achieved landmark status as the first FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3). In August 2025, the European Commission granted conditional marketing authorization for Rezdiffra, expanding its commercial footprint to Europe.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the commercial footprint of Rezdiffra (resmetirom) in the United States and Europe, supported by an expanded endocrinology field force and direct-to-consumer marketing campaigns to drive physician adoption and patient starts.
Expected impact: Sustain double-digit patient growth and solidify Rezdiffra's position as the foundational blockbuster therapy for MASH.
Building a diversified pipeline of combination therapies anchored by Rezdiffra, targeting complementary disease pathways (such as GLP-1, DGAT-2, and genetic drivers like PNPLA3) to optimize efficacy and tolerability.
Expected impact: Establish next-generation, best-in-class oral and precision medicine treatment regimens for diverse MASH patient subtypes.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Acquired global rights to SYH2086 (MGL-2086), a preclinical oral small molecule GLP-1 receptor agonist, to develop combination therapies with Rezdiffra [1.1.1].
Terms: $120 million upfront payment, up to $2 billion in development, regulatory, and commercial milestones, plus royalties on net sales.
Acquired global rights to develop, manufacture, and commercialize ervogastat (a Phase 2 oral DGAT-2 inhibitor) and two other early-stage MASH assets to study in combination with Rezdiffra.
Terms: $50 million upfront payment (recorded in Q4 2025), plus eligibility for future milestone payments and royalties on net sales.
Acquired worldwide rights to six preclinical siRNA programs targeting MASH to explore gene-silencing combinations with Rezdiffra.
Terms: $60 million upfront payment, with total potential milestone payments of up to $4.4 billion.
Acquired exclusive global rights to develop, manufacture, and commercialize ARO-PNPLA3, a clinical-stage siRNA asset targeting a key genetic driver of MASH.
Terms: $25 million upfront payment, up to $975 million in development, regulatory, and sales milestones, plus tiered royalties on net sales.